Rezolute (RZLT) Q4 2026 earnings summary

Executive summary

• Reported Q4 and full year 2026 financial results, highlighting ongoing clinical progress in ultra-rare hypoglycemia indications.

• Provided updates on Phase 3 studies for tumor HI (upLIFT) and congenital HI (sunRIZE), including interim and extension data.

Financial highlights

• Cash, cash equivalents, and investments totaled $107.8 million as of June 30, 2026, down from $167.9 million a year earlier.

• Q4 2026 net loss was $20.5 million, compared to $24.4 million in Q4 2025.

• Full year 2026 net loss was $77.6 million, up from $74.4 million in 2025.

• R&D expenses for Q4 2026 were $14.9 million (down from $20.9 million YoY); full year R&D was $53.8 million (down from $61.5 million YoY).

• G&A expenses for Q4 2026 were $6.7 million (up from $5.0 million YoY); full year G&A was $29.2 million (up from $18.4 million YoY).

Outlook and guidance

• Topline results from the upLIFT study in tumor HI expected before the end of 2026.

• Awaiting FDA feedback on the sunRIZE congenital HI study; potential for further regulatory discussions.

• Commercial preparations for ersodetug ongoing, with increased professional fees in anticipation.